FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

By
Kathryn Wighton
June 26, 2026
3 min

MDSpire News

At a Glance

Category	Detail
Condition	Triple-Negative Breast Cancer (TNBC)
Key Mechanisms	Combination of pembrolizumab with sacituzumab govitecan-hziy or chemotherapy
Target Population	Adult patients with unresectable locally advanced or metastatic TNBC expressing PD-L1 with a Combined Positive Score of 10 or greater
Care Setting	Oncology

Key Highlights

FDA approved pembrolizumab plus sacituzumab govitecan-hziy for first-line treatment of mTNBC.
Approval based on phase 3 KEYNOTE-D19/ASCENT-04 trial with 443 patients.
Pembrolizumab plus sacituzumab govitecan-hziy reduced risk of disease progression or death by 35%.
Median progression-free survival was 11.2 months for the new regimen vs. 7.8 months for chemotherapy.
Objective response rate was 61% with the new regimen compared to 55% with chemotherapy.

Guideline-Based Recommendations

Diagnosis

Diagnosis of unresectable locally advanced or metastatic TNBC with PD-L1 expression.

Management

Use pembrolizumab plus sacituzumab govitecan-hziy as a category 1 preferred first-line treatment.

Monitoring & Follow-up

Monitor for common adverse reactions including decreased blood counts and gastrointestinal symptoms.

Risks

Serious adverse reactions occurred in 38% of patients; fatal adverse reactions in 3.2%.

Patient & Prescribing Data

Patients with recurrent unresectable or stage IV PD-L1-positive TNBC.

Combination therapy offers a new first-line treatment option with improved outcomes.

Clinical Best Practices

Consider patient eligibility based on PD-L1 expression and prior treatment history.
Educate patients on potential adverse reactions and the importance of monitoring.